Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule belonging to the benzenesulfonamide class. It has been studied as an experimental inhibitor of focal adhesion kinase (FAK), a non-receptor tyrosine kinase involved in cellular adhesion and signal transduction. Structural studies have shown that it binds selectively to the catalytic domain of FAK and exhibits kinetic selectivity over proline-rich tyrosine kinase 2 (PYK2), likely due to its ability to induce helical structure at the DFG motif of FAK but not PYK2. The compound is not approved for clinical use and remains an experimental tool for biochemical and structural research on kinase inhibition[7][8].
- Other names
- 4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide4-((4-(((1R,2R)-2-(dimethylamino)cyclopentyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)-N-methylbenzene-sulfonamide4-[ (4-{[(1R,2R)-2-(dimethylamino)cyclopentyl] amino } -5 -( trifluoromethyl ) pyrimidin - 2 - yl ) amino ] - N - methylbenzene - 1 - sulfonamide
02
Targets
FAK (Focal adhesion kinase)
Beyond the preview
Go deeper on 4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide.